1. Home
  2. THG vs IMVT Comparison

THG vs IMVT Comparison

Compare THG & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hanover Insurance Group Inc

THG

Hanover Insurance Group Inc

HOLD

Current Price

$170.44

Market Cap

6.6B

Sector

Finance

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$26.13

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THG
IMVT
Founded
1852
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
5.3B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
THG
IMVT
Price
$170.44
$26.13
Analyst Decision
Buy
Buy
Analyst Count
6
9
Target Price
$196.67
$29.13
AVG Volume (30 Days)
315.0K
1.7M
Earning Date
02-03-2026
02-05-2026
Dividend Yield
2.23%
N/A
EPS Growth
73.14
N/A
EPS
17.31
N/A
Revenue
$6,506,900,000.00
N/A
Revenue This Year
$4.23
N/A
Revenue Next Year
$5.18
N/A
P/E Ratio
$9.87
N/A
Revenue Growth
5.26
N/A
52 Week Low
$147.76
$12.72
52 Week High
$188.18
$27.80

Technical Indicators

Market Signals
Indicator
THG
IMVT
Relative Strength Index (RSI) 34.20 53.73
Support Level $166.54 $25.18
Resistance Level $181.04 $27.37
Average True Range (ATR) 3.90 1.16
MACD -1.46 -0.08
Stochastic Oscillator 18.35 47.58

Price Performance

Historical Comparison
THG
IMVT

About THG Hanover Insurance Group Inc

The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business internationally through a wholly owned subsidiary, Chaucer Holdings Limited, domiciled in the United Kingdom. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: